

▶ **Preventing Post-Release Overdose Deaths
DAC-NC FIT OUD Treatment Collaboration
JRC Meeting July 2024**

Evan Ashkin MD
Director NC FIT Program
Director NC Technical Assistance Center
Professor Family Medicine UNC Chapel Hill

I have no disclosures

Slide Acknowledgements:

Some slides within this slide deck are used with permission from MAHEC, including slides titled as follows:
“Treatment of Opioid Use Disorder in Adults,” “Opioid Use Disorder Treatment and Rates of Adherence,”
“Why MOUD?,” “Economic Impact of SUDs,” “MOUD is Effective in Correctional Settings,” “MAT Pilot for
Non-Pregnant Adults & FIT Recovery: Eligible Reentry Counties.”



Drug Overdose #1 Cause of Death in the US for people under 50 yo.

- ▶ Vast Majority of overdose deaths are from Opioids
Heroin, Fentanyl.....

North Carolina Prison System

First 2 weeks post-release

Death from Overdose

50x higher

than general population


1. Opioid Overdose Deaths Among Formerly Incarcerated
Persons and the General Population: North Carolina,
2000–2018 AJPH 2022

North Carolina Prison System


“From 2017 to 2018, the OOD rates in the North Carolina general population decreased by 10.1% but increased by 32% among FIPs”

1. Opioid Overdose Deaths Among Formerly Incarcerated Persons and the General Population: North Carolina, 2000–2018 AJPH 2022


NC DAC: 74% screen + SUD



Treatment of Opioid Use Disorder in Adults



Opioid Use Disorder Treatment & Rates of Adherence



4. MAHEC, 2024.

5. Weiss R, Rao V 2017

6. Mintzer II, Eisenberg M, Terra M, et al. 2007

7. Potter J, Marino E, Hillhouse M, et al. 2013

8. Strain E, Stitzer M, Liebson I 1993

9. Lee J, Nunes E, Novo P, et al. 2018

10. Tuten M, DeFulio A, Jones H, et al. 2012

Why MOUD?

- The use of the opioid agonists methadone and buprenorphine reduces:¹



- **Buprenorphine and Methadone: 73% decrease in overdose mortality!**³
- What about Long-Acting Naltrexone (Vivitrol)?

11. NIDA 2018

12. Fairley et al. 2021

13. Bahji, Cheng, Gray, et al. 2019

4. MAHEC, 2024.

What about Naltrexone/Vivitrol?

Heavily marketed to Sheriff's associations, correctional organizations, law enforcement, drug courts, elected officials¹


- Company has pushed for decreased access to buprenorphine/methadone

Unlike methadone/buprenorphine, naltrexone does NOT induce opioid tolerance, thus has increased risk of overdose with return to use

Out of pocket cost: ~\$1000/month, compared to ~\$70/month for buprenorphine

MULTIPLE studies show NO IMPROVEMENT in overdose risk with naltrexone compared to placebo, and WORSE overdose risk compared to buprenorphine/methadone²³

Abstinence: Higher OD Deaths than No Treatment



Economic Impact of SUDs

- Treatment is less expensive than alternatives

Approximate average cost for 1 full year:

Buprenorphine treatment	Methadone treatment	Naltrexone treatment	Incarceration
\$6,000 per patient ¹	\$6,500 per patient ¹	\$14,000 per patient ¹	\$36,000 per person ²

- Including criminal justice costs, MOUD treatment saved \$25,000 to \$105,000 in lifetime costs per person ²

MOUD is Effective in Correctional Settings


Another study showed that access to MOUD during the first four weeks in prison, was associated with a **94% reduction in risk of death**, primarily associated with a reduction of suicide deaths among incarcerated people.³

After expanding MOUD statewide, the Rhode Island Department of Corrections saw a **61% reduction** in post-correctional overdose death rates in the first year.¹

A study of >12,000 people in England found that a prison-based MOUD program was linked with a **75% reduction in all-cause mortality and an 85% reduction in overdose deaths** in the first month after release.²

Medication-Assisted Treatment helps reduce fatal overdoses

Fatal overdoses in the first 6 months of the year fell after the Rhode Island DOC implemented a MAT program in 2016



21. Green, Clarke, Brinkley-Rubinstein 2018

22. Marsden, Stillwell, Jones, Eastwood, Farrell 2017

23. Larney, Gisev, Farrell, Dobbins, Burns, Gibson, Kimber, Degenhardt 2018

20. MAHEC 2023.

What the Literature Shows about MOUD in Jails/Prisons

Follow up from RIDOC Prison MOUD Program:

- 1,600 people enrolled
- 12 Overdose Deaths <1%
- 1 OD Death in 1st 2 weeks post-release
- **12 months post-release: 86% engaged in MOUD**

*The Lancet Regional
Health - Americas
2023;18: 100419*

What the Literature Shows about MOUD in Jails/Prisons

Increases post release treatment rates

Decrease post release overdose rates, substance use

Lowers criminal activity, rearrests, probation violations, suicide in jail, behavior issues in jail

Improves family relationships, employment

Cost effective!

MAT in Prison Pilot (MIPP)

Partnership DAC-MAHEC-NC FIT

Planning starts 4/2021

Pilot Sites: NC Correctional Institute for Women (NCCIW)
Orange Correctional

- MAHEC:
 - ❖ Screen for participants
 - ❖ Initial telehealth evaluation
 - ❖ Enroll in MIPP
 - ❖ Initiate MOUD with oral Suboxone → Sublocade injection prior to release

MAT in Prison Pilot (MIPP)

Partnership DAC-MAHEC-NC FIT


MOUD Initiations begin:

NCCIW: 7/2022

Orange 10/2022

NC FIT: FIT Recovery links people to community MOUD provider, combination of FQHCs and OTPs

- ❖ FIT Recovery Network now covers nearly 60 Counties
 - ❖ FIT CHW makes contact pre-release, follows post-release
 - ❖ Pays for visits and meds for 1st 6 mos. post-release



gram County

*Clinics will **only** accept residents of the indicated county.*



Eligible Neighboring County of Clinic Site

Residents of these counties must have reliable transportation to a neighboring county in gray to receive care.

MAT in Prison Pilot (MIPP)

Outcomes



Inception-1/24

- 696 people referred
 - ❖ 377 ineligible
 - ❖ 272 interviewed
 - ❖ 187 enrolled

MAT in Prison Pilot (MIPP)

173
Participants Initiated
on MOUD

Across **2** Prisons



MAT in Prison Pilot (MIPP)

Outcomes

- 188 people released
 - ❖ 116 released to FIT Eligible County
 - ❖ 80 FIT intakes completed post-release – 70%

83% attended First clinic appt to continue MOUD

Future of FIT Recovery Program

- Continue collaboration with DAC to assist all people being released with Opioid Use Disorder who have been initiated on Suboxone (Buprenorphine)
- Build out FIT Recovery Network to try and cover all counties in NC
 - UNC Star Network
 - Opioid Treatment Programs
 - Broaden FQHC partnerships
 - Potential pilot community pharmacies and county health directors

References

1. Ranapurwala SI, Figgatt MC, Remch M, et al. Opioid Overdose Deaths Among Formerly Incarcerated Persons and the General Population: North Carolina, 2000–2018. *Am J Public Health*. 2022;112(2):300-303. doi:10.2105/AJPH.2021.3066
2. FY 2019-2020 Offender Admissions Identified with a Substance Use Problem and Number of Daily Treatment Slots Available. NC Department of Adult Corrections.
3. SAMHSA. Medication-Assisted Treatment (MAT). SAMHSA. Published July 25, 2022. Accessed October 13, 2022. <https://www.samhsa.gov/medication-assisted-treatment>
4. UNC Health Sciences at MAHEC. Medication for Opioid Use Disorder (MOUD 101). 2024. Asheville, NC'
5. Weiss RD, Rao V. The Prescription Opioid Addiction Treatment Study: What have we learned. *Drug Alcohol Depend*. 2017;173 Suppl 1:S48-S54. doi:10.1016/j.drugalcdep.2016.12.001
6. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. *Ann Fam Med*. 2007;5(2):146-50.
7. Potter, J. S., Marino, E. N., Hillhouse, M. P., Nielsen, S., Wiest, K., Canamar, C. P., ... Ling, W. (2013). Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). *Journal of Studies on Alcohol and Drugs*, 74(4), 605–13. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/23739025>
8. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. *Ann Intern Med*. 1993;119(1):23-27.
9. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet*. 2018;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-X
10. Tuten M, DeFulio A, Jones HE, Stitzer M. Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. *Addiction*. 2012;107(5):973-982. doi:10.1111/j.1360-0443.2011.03750.x
11. National Institute on Drug Abuse. *Effective Treatments for Opioid Addiction*. National Institutes on Drug Abuse; 2016. Accessed July 10, 2018. <https://nida.nih.gov/publications/effective-treatments-opioid-addiction>
12. Fairley M, Humphreys K, Joyce VR, et al. Cost-effectiveness of Treatments for Opioid Use Disorder. *JAMA Psychiatry*. 2021;78(7):767. doi:10.1001/jamapsychiatry.2021.0247
13. Bahji A, Cheng B, Gray S, Stuart H. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2019;140(4):313-339. doi:10.1111/acps.13088

References

14. Harper, J. (2017) 'A Drugmaker Tries To Cash In On The Opioid Epidemic, One State Law At A Time', *National Public Radio*. Available at: <https://www.npr.org/sections/health-shots/2017/06/12/523774660/a-drugmaker-tries-to-cash-in-on-the-opioid-epidemic-one-state-law-at-a-time> (Accessed: 2024).
15. Wakeman SE, Laroche MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Netw Open*. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
16. Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. *Drug Alcohol Depend*. 2019;200:34-39. doi:10.1016/j.drugalcdep.2019.02.031
17. Heimer R, Black AC, Lin H, et al. Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016-17. *Drug Alcohol Depend*. 2024;254:111040. doi:10.1016/j.drugalcdep.2023.111040
18. ASAM. Access to Medications Talking Points. <https://www.asam.org/docs/default-source/advocacy/mat-talking-points-final.pdf?sfvrsn=0>. Accessed July 10, 2018.
19. Huang L (SAMHSA/OPPI). Medication-Assisted Treatment (MAT) in the Criminal Justice System: Brief Guidance to the States. *SAMHSA*..8. March 2019.
20. UNC Health Sciences at MAHEC. Opioid Use Disorder and the Criminal Justice System. 2023. Asheville, NC.
21. Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. *JAMA Psychiatry*. 2018;75(4):405-407. doi:10.1001/jamapsychiatry.2017.4614
22. Marsden, J., Stillwell, G., Jones, H., Cooper, A., Eastwood, B., Farrell, M., . . . Hickman, M. (2017). Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. *Addiction*, 112, 1408-1418.
23. Larney, S., Gisev, N., Farrell, M., Dobbins, T., Burns, L., Gibson, A., Kimber, J., & Degenhardt, L. (2018). Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. *BMJ Open*, 4, e004666.
24. Martin, et al. Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study. *The Lancet Regional Health - Americas* 2023;18: 100419 Published Online 23 December 2022 <https://doi.org/10.1016/j.lana.2022.100419>
25. Cates L, Brown AR. Medications for opioid use disorder during incarceration and post-release outcomes. *Health Justice*. 2023;11(1):4. Published 2023 Feb 4. doi:10.1186/s40352-023-00209-w
26. Chatterjee A, Weitz M, Savinkina A, et al. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. *JAMA Netw Open*. 2023;6(4):e237036. doi:10.1001/jamanetworkopen.2023.7036
27. Christensen, S. MAT Pilot for Non-Pregnant Adults & FIT Recovery: Eligible Reentry Counties. MAHEC, 2024. Asheville, NC.